

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: October 1, 2003 (use as many sheets as necessary)			<b>Complete if Known</b> Application Number: 10167648 Filing Date: 09/30/2003 First Named Inventor: Kohei Nishikawa et al. Group Art Unit: 1614 Examiner Name: SPINACK Attorney Docket Number: 087147-0489		
Sheet	1	of	5		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
PS ↓	A1	5,128,356	A	Naka et al.	07-07-1992	
	A2	5,162,326	A	Naka et al.	11-10-1992	
	A3	5,183,899	A	Naka et al.	02-02-1993	
	A4	5,196,444	A	Naka et al.	03-23-1993	
	A5	5,250,554	A	Naka et al.	10-05-1993	
	A6	5,284,661	A	Morimoto et al.	02-08-1994	
	A7	5,719,173	A	Nishikawa et al.	02-17-1998	
	A8	5,889,036	A	Nishikawa et al.	03-30-1999	
	A9	6,319,938	B	Nishikawa et al.	11-20-2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
PS ↓	A10	EP	0 392 317	A2	THOMAE GmbH DR K	10-17-1990		
	A11	EP	0 400 835	A1	MERCK & CO. INC.	12-05-1990		
	A12	EP	0 430 300	A2	TAKEDA CHEMICAL INDUSTRIES, LTD.	06-05-1991		
	A13	EP	0 434 038	A1	TAKEDA CHEMICAL INDUSTRIES, LTD.	06-26-1991		
	A14	EP	0 425 921	A1	TAKEDA CHEMICAL INDUSTRIES, LTD.	05-08-1991		
	A15	EP	0 445 811	A2	TAKEDA CHEMICAL INDUSTRIES, LTD.	09-11-1991		
	A16	EP	0 461 039	A1	ROUSSEL UCLAF	11-12-1991		
	A17	EP	0 591 136	A1	BOEHRINGER INGELHEIM KG (DE); RITZAU PARI WERK GMBH PAUL	03-07-1991		
	A18	EP	0 483 683	A2	TAKEDA CHEMICAL INDUSTRIES, LTD.	05-06-1992		
	A19	EP	0 518 033	A1	TAKEDA CHEMICAL INDUSTRIES, LTD.	12-16-1992		
	A20	EP	0 520 423	A2	TAKEDA CHEMICAL INDUSTRIES, LTD.	12-30-1992		
	A21	EP	0 588 299	A2	TAKEDA CHEMICAL INDUSTRIES, LTD.	03-23-1994		
	A22	EP	0 603 712	A2	TAKEDA CHEMICAL INDUSTRIES, LTD.	06-29-1994		

Examiner Signature	Phyllis Spinack	Date Considered	7/10/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: October 1, 2003 (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	Unassigned
		Filing Date	09/30/2003
		First Named Inventor	Kohei Nishikawa et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	087147-0489
Sheet	3	of	5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PS	A33	LAI et al., "Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial," <u>Clin. Neph.</u> , 1986, pp. 174-180, Vol. 26, No. 4,	
	A34	BALOW et al., "Effect of treatment on the evolution of renal abnormalities in lupus nephritis," <u>New Engl. J. Med.</u> , August 23, 1984, p. 491, Vol. 311, No. 8, USA.	
	A35	BRAZY et al., "Progression of renal insufficiency; role of blood pressure," <u>Kidney Int.</u> , 1989, pp. 670-674, Vol. 35, © International Society of Nephrology, USA.	
	A36	RAIJ, "Role in hypertension in progressive glomerular injury in glomerulonephritis," <u>Hypertension</u> , 1986, pp. 30-33, Vol. 8, Suppl. 1.	
	A37	COPPER et al., "Nephropathy in Model Combining Genetic Hypertension with Experimental Diabetes, Enalapril Versus Hydralazine and Metoprolol Therapy," <u>Diabetes</u> , December 1990, pp. 1575-1579, Vol. 39.	
	A38	FERDER et al., "Angiotensin Converting Enzyme Inhibitors Versus Calcium Antagonists in the Treatment of Diabetic Hypertensive Patients," <u>Hypertension</u> , February 1992, pp. II-237-II-242, Vol. 19, No. 2, Suppl. II, Argentina.	
	A39	WOLF et al., "Angiotensin II Stimulates the Proliferation and Biosynthesis of Type I Collagen in Cultured Murine Mesangial Cells," <u>Am. J. Path.</u> , January 1992, pp. 95-107, Vol. 140, No. 1, © American Association of Pathologists, USA.	
	A40	ANDERSON et al., "Angiotensin II causes mesangial cell hypertrophy," <u>Hypertension</u> , 1993, pp. 29-35, Vol. 21,	
✓	A41	REDDI et al., "Enalapril Improves Albuminuria by Preventing Glomerular Loss of Heparan Sulfate in Diabetic Rats," <u>Biochem. Med. &amp; Met. Bio.</u> , 1991, pp. 119-131, Vol. 45, © Academic Press, Inc.	

Examiner Signature	Phyllis Spivack	Date Considered	7/10/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	Unassigned
		Filing Date	08/30/2003
Date Submitted: October 1, 2003 (use as many sheets as necessary)		First Named Inventor	Kohei Nishikawa et al.
		Group Art Unit	Unassigned
Sheet 4 of 5		Examiner Name	Unassigned
		Attorney Docket Number	087147-0489

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PS	A42	MORRELL et al., "Effects of Converting-Enzyme Inhibition on Barrier Function in Diabetic Glomerulopathy," <u>Diabetes</u> , January 1990, pp. 76-82, Vol. 39.	
	A43	KLEIN et al., "Glomerular Proteoglycans in Diabetes, Partial Structural Characterization and Metabolism of De Novo Synthesized Heparan- <sup>35</sup> SO <sub>4</sub> and Dermatan- <sup>35</sup> SO <sub>4</sub> Proteoglycans in Streptozocin-Induced Diabetic Rats," <u>Diabetes</u> , October 1986, p. 1130, Vol. 35.	
	A44	BOHM et al., "The Angiotensin II Antagonist BIBR277 Normalized Blood Pressure and Improves. . ." <u>The FASEB Jnl.</u> 7(3):A246 (1993).	
	A45	DUNN, "Prostaglandins, Angiotensin II, and Proteinuria," <u>Nephron</u> , 5:30-37 (1990).	
	A46	HONMA et al., "Renal protective effects of the angiotensin II (Ang II) receptor antagonist CV-11974. . .," <u>JANS</u> 4:513 (1993).	
	A47	KOHARA et al., "Angiotensin Blockade and the Progression of Renal Damage in the Spontaneously Hypertensive Rat," <u>Hypertension</u> 21(6):975-979 (1993).	
	A48	MackENZIE et al., <u>Journal of the American Society of Nephrology</u> 4(3):775 (abstract).	
	A49	NODA et al., "Inhibition of Rabbit Aortic Angiotensin II (All) Receptor by CV-11974, A New Nonpeptide All Antagonist," <u>Bio. Pharm.</u> 46(2):311-318 (1993).	
	A50	SHIBOUTA et al., <u>Japanese Pharmacology and Therapeutics</u> , 21(5):227-235 (abstract) 1993.	

Examiner Signature	<i>Phillip Spinnack</i>	Date Considered	7/10/05
--------------------	-------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: October 1, 2003 (use as many sheets as necessary)		Application Number	Unassigned
		Filing Date	09/30/2003
		First Named Inventor	Kohei Nishikawa et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	5	of	5
		Attorney Docket Number	087147-0489

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
PS	A51	WOLF et al., "Glucose-Induced Hypertrophy in Cultured Proximal Tubule Cells: Enhancement by Angiotensin II (All)," <u>The FASEB Jnl.</u> 5(5):A1039 (1991).	

Examiner Signature	<i>Phyllis Sawack</i>	Date Considered	7/10/05
--------------------	-----------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: October 1, 2003 (use as many sheets as necessary)			<b>Complete if Known</b>	
			Application Number	
			Filing Date	
			First Named Inventor	
			Group Art Unit	
			Examiner Name	
Attorney Docket Number				

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
ps ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓	A1	5,128,356	A	Naka et al.	07-07-1992	
	A2	5,162,326	A	Naka et al.	11-10-1992	
	A3	5,183,899	A	Naka et al.	02-02-1993	
	A4	5,196,444	A	Naka et al.	03-23-1993	
	A5	5,250,554	A	Naka et al.	10-05-1993	
	A6	5,284,661	A	Morimoto et al.	02-08-1994	
	A7	5,719,173	A	Nishikawa et al.	02-17-1998	
	A8	5,889,036	A	Nishikawa et al.	03-30-1999	
	A9	6,319,938	B	Nishikawa et al.	11-20-2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
PS ↓<								

Examiner Signature	phyllis Spivack	Date Considered	7/10/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Substitute for form 1449B/PTO

**Date Submitted: October 1, 2003**

(use as many sheets as necessary)

Sheet	2	of	5
-------	---	----	---

<b>Application Number</b>	Unassigned
<b>Filing Date</b>	09/30/2003
<b>First Named Inventor</b>	Kohei Nishikawa et al.
<b>Group Art Unit</b>	Unassigned
<b>Examiner Name</b>	Unassigned
<b>Attorney Docket Number</b>	087147-0489

[illegible]

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
PS ↓ ✓	A26	CATTELL, "Macrophages in acute glomerular inflammation," <u>Kidney Int.</u> , 1994, pp. 945-952, Vol. 45, © International Society of Nephrology, London, England .	
	A27	EL NAHAS, "Growth factors and glomerular sclerosis," <u>Kidney Int.</u> , 1992, pp. S15-S20, Vol. 41, Suppl. 36© International Society of Nephrology, Sheffield, United Kingdom .	
	A28	OKUDA et al., "Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis," <u>J. Clin. Invest.</u> , August 1990, pp. 453-462, Vol. 86, © The American Society for Clinical Investigation, Inc., USA .	
	A29	COUSER, "Pathogenesis of glomerulonephritis," <u>Kidney Int.</u> , 1993, pp. S19-S26, Vol. 44, Suppl. 42, © International Society of Nephrology, Seattle, Washington, USA .	
	A30	ZATZ et al., "Pathogenesis of Diabetic Microangiopathy, The Hemodynamic View," <u>Am. J. Med.</u> , March 1986, pp. 443-453, Vol. 80, USA .	
	A31	MOUSTONEN et al., "The nephrotic syndrome in IgA glomerulonephritis, response to corticosteroid therapy," <u>Clin. Nephrol.</u> , 1983, p. 172, Vol. 20, No. 4,	
	A32	SATO et al., "Clinical and histological characteristics of patients with IgA nephropathy showing massive proteinuria," <u>Jp. Nephrol.</u> , 1986, p. 1179, Vol. 28, No. 9 ,	

**Examiner  
Signature**

Phyllis Spinack

Date Considered

7/10/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: October 1, 2003 (use as many sheets as necessary)		Application Number	Unassigned
		Filing Date	09/30/2003
		First Named Inventor	Kohei Nishikawa et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	087147-0489
Sheet	3	of	5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
PS	A33	LAI et al., "Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial," <u>Clin. Neph.</u> , 1986, pp. 174-180, Vol. 26, No. 4,	
	A34	BALOW et al., "Effect of treatment on the evolution of renal abnormalities in lupus nephritis," <u>New Engl. J. Med.</u> , August 23, 1984, p. 491, Vol. 311, No. 8, USA.	
	A35	BRAZY et al., "Progression of renal insufficiency; role of blood pressure," <u>Kidney Int.</u> , 1989, pp. 670-674, Vol. 35, © International Society of Nephrology, USA.	
	A36	RAIJ, "Role in hypertension in progressive glomerular injury in glomerulonephritis," <u>Hypertension</u> , 1986, pp. 30-33, Vol. 8, Suppl. 1.	
	A37	COPPER et al., "Nephropathy in Model Combining Genetic Hypertension with Experimental Diabetes, Enalapril Versus Hydralazine and Metoprolol Therapy," <u>Diabetes</u> , December 1990, pp. 1575-1579, Vol. 39.	
	A38	FERDER et al., "Angiotensin Converting Enzyme Inhibitors Versus Calcium Antagonists in the Treatment of Diabetic Hypertensive Patients," <u>Hypertension</u> , February 1992, pp. II-237-II-242, Vol. 19, No. 2, Suppl. II, Argentina.	
	A39	WOLF et al., "Angiotensin II Stimulates the Proliferation and Biosynthesis of Type I Collagen in Cultured Murine Mesangial Cells," <u>Am. J. Path.</u> , January 1992, pp. 95-107, Vol. 140, No. 1, © American Association of Pathologists, USA.	
	A40	ANDERSON et al., "Angiotensin II causes mesangial cell hypertrophy," <u>Hypertension</u> , 1993, pp. 29-35, Vol. 21,	
✓	A41	REDDI et al., "Enalapril Improves Albuminuria by Preventing Glomerular Loss of Heparan Sulfate in Diabetic Rats," <u>Biochem. Med. &amp; Met. Bio.</u> , 1991, pp. 119-131, Vol. 45, © Academic Press, Inc.	

Examiner Signature	Phyllis Spivack	Date Considered	7/10/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: October 1, 2003 (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	Unassigned
		Filing Date	09/30/2003
		First Named Inventor	Kohei Nishikawa et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	087147-0489
Sheet	4	of	5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PS	A42	MORRELL et al., "Effects of Converting-Enzyme Inhibition on Barrier Function in Diabetic Glomerulopathy," <u>Diabetes</u> , January 1990, pp. 76-82, Vol. 39.	
	A43	KLEIN et al., "Glomerular Proteoglycans in Diabetes, Partial Structural Characterization and Metabolism of De Novo Synthesized Heparan- <sup>35</sup> SO <sub>4</sub> and Dermatan- <sup>35</sup> SO <sub>4</sub> Proteoglycans in Streptozocin-Induced Diabetic Rats," <u>Diabetes</u> , October 1986, p. 1130, Vol. 35.	
	A44	BOHM et al., "The Angiotensin II Antagonist BIBR277 Normalized Blood Pressure and Improves. . ." <u>The FASEB Jnl.</u> 7(3):A246 (1993).	
	A45	DUNN, "Prostaglandins, Angiotensin II, and Proteinuria," <u>Nephron</u> , 5:30-37 (1990).	
	A46	HONMA et al., "Renal protective effects of the angiotensin II (Ang II) receptor antagonist CV-11974. . .," <u>JANS</u> 4:513 (1993).	
	A47	KOHARA et al., "Angiotensin Blockade and the Progression of Renal Damage in the Spontaneously Hypertensive Rat," <u>Hypertension</u> 21(6):975-979 (1993).	
	A48	MackENZIE et al., <u>Journal of the American Society of Nephrology</u> 4(3):775 (abstract).	
	A49	NODA et al., "Inhibition of Rabbit Aortic Angiotensin II (All) Receptor by CV-11974, A New Nonpeptide All Antagonist," <u>Bio. Pharm.</u> 46(2):311-318 (1993).	
	A50	SHIBOUTA et al., <u>Japanese Pharmacology and Therapeutics</u> , 21(5):227-235 (abstract) 1993.	

Examiner Signature	Phyllis Samack	Date Considered	7/10/05
--------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: October 1, 2003 (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	Unassigned
		Filing Date	09/30/2003
		First Named Inventor	Kohei Nishikawa et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	087147-0489
Sheet	5	of	5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
PS	A51	WOLF et al., "Glucose-Induced Hypertrophy in Cultured Proximal Tubule Cells: Enhancement by Angiotensin II (All)," <u>The FASEB Jnl.</u> 5(5):A1039 (1991).	

Examiner Signature	Amelis Spivack	Date Considered	7/10/05
--------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.